{
  "docId": "019de076-b279-75da-94b2-8ad8944b7652",
  "docSlug": "3080df08d7a75d95f523d4df26f037ae",
  "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 29 slides",
  "authorId": "matinas-biopharma",
  "authorName": "Matinas BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 29,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "Focuses on clinical success in a compassionate use setting.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b279-75da-94b2-8ad8944b7652/12",
  "deckHref": "/decks/019de076-b279-75da-94b2-8ad8944b7652",
  "deckJsonHref": "/decks/019de076-b279-75da-94b2-8ad8944b7652.json",
  "deckAnchorHref": "/decks/019de076-b279-75da-94b2-8ad8944b7652#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.07,
        "w": 0.92,
        "x": 0.04,
        "y": 0.17
      },
      "kind": "callout",
      "text": "Demonstrated Efficacy in Treatment of Patients with Limited Treatment Options",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a3856dc9-53a1-4cd3-803e-e19cba6117c3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.92,
        "x": 0.04,
        "y": 0.27
      },
      "kind": "list",
      "text": "14 patients with no other treatment options are currently receiving or have completed treatment with MAT2203. Notable Healthcare Institutions: NIH, University of Michigan, Johns Hopkins, City of Hope, Nationwide Children’s Hospital, Vanderbilt University Medical Center, Children’s Hospital of Philadelphia.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2677000c-1eaf-4afc-90c4-66ef030035af",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.92,
        "x": 0.04,
        "y": 0.82
      },
      "kind": "list",
      "text": "All patients who received at least two weeks or more of treatment had positive clinical outcomes with significant success stories of full recovery in majority of patients.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5754d98e-94e8-4533-bc11-d593db4b3c40",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.92,
        "x": 0.04,
        "y": 0.55
      },
      "kind": "list",
      "text": "Patients were switched to treatment with IV Amphotericin B with clinical response but unable to tolerate treatment due renal toxicity. All patients hospitalized to monitor/manage renal safety and most received IV electrolyte supplementation.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5cbff180-18ce-4990-84f9-92b88de223a1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.92,
        "x": 0.04,
        "y": 0.48
      },
      "kind": "list",
      "text": "Patients were not responding/resistant to, or unable to receive, azole therapy.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7fadb795-7159-4eb2-9ff2-eb0a0eb845af",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.92,
        "x": 0.04,
        "y": 0.7
      },
      "kind": "list",
      "text": "Following oral MAT2203 initiation, patients were discharged to continue treatment at home.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "862dbb27-b8ab-4595-afd3-022e83ce4d54",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.92,
        "x": 0.04,
        "y": 0.76
      },
      "kind": "list",
      "text": "Renal toxicity reversed and renal function returned to baseline.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d3b72581-13dc-4e9a-910b-5ed30e60b54e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "MAT2203 Expanded Access/Compassionate Use Program",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "22902531-7c69-43b5-88e2-d66e11718cc8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "58c38c95-7fda-4b64-9407-437e4107c397",
      "evidence": "14 patients with no other treatment options are currently receiving or have completed treatment with MAT2203. Notable Healthcare Institutions: NIH, University of Michigan, Johns Hopkins, City of Hope, Nation",
      "confidence": 0.7
    },
    {
      "name": "Story Moments",
      "slug": "story-moments",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "ddec9ab3-3cf7-4715-a601-9c011c6c2ab9",
      "evidence": "All patients who received at least two weeks or more of treatment had positive clinical outcomes with significant success stories of full recovery in majority of patients.",
      "confidence": 0.6
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 7,
      "beatId": "7aa25a8a-9932-4625-b5d8-1d7641445816",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Problem (Identify pain)",
      "beatSlug": "problem-agitate-solution-problem-identify-pain",
      "evidence": "The document identifies the growing threat of IFIs and high unmet medical need in IA",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    },
    {
      "to": 17,
      "from": 8,
      "beatId": "eafaf135-71d7-4ccf-a416-5600c022e3da",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents MAT2203 as a solution and provides supporting evidence",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "280995d8-784d-4cf6-887d-11df1485e9b8",
      "evidence": "The document emphasizes the growing threat of IFIs",
      "position": 0,
      "objective": "Highlight the consequences of not addressing IFIs",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}